

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Effect of Lymphocyte miRNA Expression on Influenza Vaccine-Induced Immunity

Iana H. Haralambieva¹, Tamar Ratishvili¹, Krista M. Goergen², Diane E. Grill², Whitney L. Simon¹, Jun Chen², Inna G. Ovsyannikova¹, Gregory A. Poland¹, Richard B. Kennedy¹

¹Mayo Clinic Vaccine Research Group, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA

Running Head: Lymphocyte miRNA Expression and Influenza Vaccine-Induced Immunity

Keywords: Influenza Vaccine; Immunity; MicroRNA Expression, T Cells, B Cells, NK Cells

Abstract Word Count: 207

Word Count: 3,857

Address correspondence to:

Richard B. Kennedy, Ph.D., Co-Director, Mayo Vaccine Research Group, Mayo Clinic, Guggenheim 611D, 200 First Street SW, Rochester, Minnesota 55905
Phone: (507) 284-0708; Fax: (507) 266-4716; Email: kennedy.rick@mayo.edu

©Copyright 2024 Mayo Foundation for Medical Education and Research

25 Highlights

- 26 • Host miRNA expression is relatively stable before and after influenza vaccination
- 27 • miR-150-3p, miR-629-5p and miR-4443 were correlated with immunity across cell types
- 28 • Specific CD4⁺ T cell miRNAs are predictive of antibody responses
- 29 • Identified miRNAs may serve as biomarkers of immune response after influenza vaccine

30 Abstract

31 Alterations of gene expression by miRNAs contribute substantially to genetic regulation and
32 cellular functions.

33 We conducted a comprehensive study in 53 individuals before and after the administration of the
34 2010-2011 seasonal inactivated influenza vaccine to characterize lymphocyte-specific miRNA
35 expression (in purified B cells, CD4⁺ T cells, CD8⁺ T cells and NK cells) and its effect on
36 influenza vaccine-induced immune outcomes (hemagglutination inhibition antibody titers/HAI,
37 viral neutralizing antibody titers /VNA and memory B cell ELISPOT).

38 Overall, we observed relatively stable miRNA expression before/after influenza vaccination. Our
39 statistical analysis uncovered three baseline miRNAs (miR-150-3p, miR-629-5p and miR-4443)
40 that were significantly correlated with influenza vaccine-induced immune outcomes in different
41 cell types. Predictive modeling of influenza vaccine-induced HAI/VNA titers identified a set of
42 specific baseline miRNAs in CD4⁺ T cells as factors predictive of antibody responses. A
43 pathway enrichment analysis on the putative target genes revealed several regulated signaling
44 pathways and functions: TGF- β signaling, PI3K-Akt signaling, p53 signaling, MAPK signaling,
45 TNF signaling and C-type lectin receptor signaling, as well as cell adhesion and adherens
46 junctions, and antiviral host response.

47 In conclusion, our study offers evidence for the role of epigenetic modification (miRNAs) on
48 influenza vaccine-induced immunity. After validation, identified miRNAs may serve as potential
49 biomarkers of immune response after influenza vaccination.

50

51

52 **Introduction**

53 Influenza virus is a pathogen of major public health concern. Seasonal outbreaks can involve
54 millions of cases in the United States and countless more worldwide. Influenza morbidity and
55 mortality is increased in infants, young children, and the elderly. While the impact of influenza
56 on human health has been ameliorated through the use of vaccination, vaccine efficacy rates vary
57 greatly from year to year, indicating a need for the development of improved influenza vaccines,
58 especially in those vulnerable populations. Systems biology studies and high-dimensional
59 platforms are often utilized to comprehensively assess the human transcriptome in order to
60 elucidate how protective immunity develops and is maintained after vaccination and to discover
61 potential biomarkers of protective immunity.

62 MicroRNAs (miRNAs) are 21-23 nucleotide sequences that modulate gene expression by
63 binding to the 3' UTR of target mRNAs [1]. They control key biological processes and modulate
64 innate and adaptive antiviral responses. Host miRNAs have also been demonstrated to affect
65 viral gene expression and viral miRNAs have been shown to affect host gene expression [2, 3].
66 miRNA profiling studies of viral infection have highlighted the important regulatory effect of
67 noncoding RNAs on immune response [2-4].

68 The goal of the study was to comprehensively assess lymphocyte-specific miRNA expression
69 before and after influenza vaccination and to identify baseline/early miRNA biomarkers
70 associated with, and perhaps predictive of, immune response to influenza vaccination.

71

72 **Methods**

73 The methods described here are similar or identical to the ones in our previously published
74 studies [5-8].

75

76 *Study subjects*

77 A subgroup of 53 people was randomly selected from a previously recruited cohort of 159 older
78 adults (50-74 years old, males and females) in good general health [7]. Individuals received the
79 2010-2011 trivalent inactivated influenza vaccine. This vaccine contained the
80 A/California/7/2009 H1N1-like, A/Perth/16/2009 H3N2-like, and B/Brisbane/60/2008-like
81 strains. Blood samples were collected before vaccination (Day 0) and at Day 3 and Day 28 post-
82 vaccination. The Mayo Clinic Institutional Review Board approved all study procedures and
83 written informed consent was obtained from each participant.

84

85 *Immunologic Testing*

86 Influenza A/California/7/2009/H1N1-specific hemagglutination inhibition (HAI) titers, viral
87 microneutralization assay (VNA) titers, and B cell ELISPOTs were performed using serum and
88 PBMCs from each subject at each timepoint, as previously described [7, 8].

89

90 *Cell purification and miRNA isolation*

91 Cryopreserved PBMCs were thawed using standard procedures; stained with fluorescently
92 labeled antibodies to CD3, CD4, CD8, CD19, and CD56 (BD Biosciences; San Jose, CA); and
93 sorted by fluorescence-activated cell sorting using a FACS Aria (BD Biosciences; San Jose, CA).
94 CD4⁺ T cells, CD8⁺ T cells, CD3-CD56⁺ NK cells, and CD19⁺ B cells were sorted into cold
95 PBS containing 2% fetal bovine serum. Total RNA, including miRNA, was extracted using
96 miRNeasy Mini Kits (Qiagen; Valencia, CA) according to the manufacturer's instructions.

97

98 *Next Generation Sequencing*

99 Extracted miRNA quantity and quality were assessed using an Agilent 2100 Bioanalyzer
100 (Agilent; Palo Alto, CA). Illumina TruSeq miRNA library construction and single-end read
101 sequencing on Illumina HiSeq 2000 (Illumina; San Diego, CA) was performed at the Mayo
102 Clinic Advanced Genomics Technology Center as previously described [5, 9, 10] with twelve
103 samples multiplexed per lane. Subjects were randomized prior to library preparation and three
104 subjects, each with four cell types, were allocated to a lane; hence, all lanes were balanced by
105 cell type.

106 *Bioinformatics*

107 The bioinformatics pipeline has been previously described [5]. The processing of the FASTQ
108 files was done using a comprehensive pre-processing and analytical pipeline (CAP-miRNA)
109 [11] that assesses read quality (FastQC); trims adapter sequences (Cutadapt); and aligns reads for
110 Integrative Genomics Viewer (IGV) viewing and detection of mature, precursor, and novel
111 miRNAs (miRDeep2) [12].

112

113 *Statistical Analysis*

114 The primary analysis focused on the association between immune response variables (HAI, VNA
115 and B cell ELISPOT) and the expression of each mature miRNA by cell subset (CD4+ T cell,
116 CD8+ T cell, B cell, and NK cell). In addition, analyses were conducted to examine changes over
117 time in mature miRNA expression within cell subsets. For each cell subset, non-expressed
118 miRNAs (median counts of zero at all timepoints) were removed from further analysis for that
119 cell subset. In total, 129 B cell, 127 CD4+ T cell, 105 CD8+ T cell, and 103 NK cell samples
120 were carried forward for normalization and analysis. Normalization was done separately for each

121 cell subset using the trimmed mean of M-values method [13] as implemented in the edgeR
122 package [14] in R. A per cell subset post-normalization filter removed miRNA where the
123 median count at each visit were all less than or equal to 4. All correlation analyses were
124 computed using Spearman's correlation and the normalized values of miRNA expression data.
125 Changes over time in miRNA were compared using Generalized Estimating Equations (GEE)
126 [15] to account for the within-subject correlation. Per-miRNA negative binomial GEE models
127 were fit in SAS© using miRNA as the response variable and the timepoint as the independent
128 variable. The normalization offset and tagwise dispersion were estimated in edgeR [14]. False
129 discovery rate control (BH procedure) was performed to correct for multiple testing and both p-
130 values and FDR-adjusted p-values or q-values were reported. Multivariable models for each of
131 the immune response variables were created using cross-validated, elastic-net penalized
132 regression models, with the tuning parameter $\alpha = 0.9$ [16]. Models were developed separately for
133 each immune response outcome (HAI, VNA or B-cell ELISPOT); cell subset; and timepoint.
134 The dependent variable in each model was the immune response outcome at Day 28 minus the
135 response at Day 0 (log₂ scale), while the normalized miRNA expression values were the
136 independent variables. In order to reduce signal noise, only 25% of the miRNAs with the highest
137 variability between subjects were considered in each model. Sex was included in the models as a
138 covariate. The R package "multiMiR" [17] was used to identify genes representing validated
139 targets of miRNAs of interest. Identified target genes were used in the "clusterProfiler" R
140 package to identify enriched biological (KEGG) pathways regulated by the miRNAs of interest
141 [18]. Results were reported with gene ratio, which represents the ratio of the input genes that are
142 annotated in a term, and FDRs (q-values) of enrichment.
143

144 **Results**

145

146 *miRNA profiles of lymphocyte subsets*

147 Cell subset- (CD4⁺ T cell, CD8⁺ T cell, B cell, and NK cell) specific miRNA expression

148 demonstrated that, overall, miRNA expression was similar across different cell types and

149 relatively stable (for most cell subsets) in response to vaccination. Figure 1A displays the

150 common Day 0 miRNA expression between different cell types (miRNA expression overlap), as

151 well as cell type-specific miRNA expression. Supplementary Fig.1 illustrates a heatmap

152 clustering of miRNA expression by cell subset. 683 miRNAs had median counts > 0. Of those

153 412 miRNAs with a median count > 4 (post-normalization filter), CD4⁺ T cells expressed 358,

154 CD8⁺ T cells expressed 324, NK cells expressed 321, and B cells expressed 301. 62.6% of these

155 miRNAs were expressed in all four lymphocytes, while cell type-specific miRNAs were

156 relatively rare (Fig. 1A). Our initial hypothesis was that shared miRNAs would be involved

157 primarily in cytoskeletal activity, cell cycle control, proliferation/apoptosis, and other

158 housekeeping activities, while cell subset-specific miRNAs (Table 1) would reflect each

159 lymphocyte's unique immunologic function. Pathway analysis of the predicted targets of cell

160 subset-specific miRNAs, however, indicated that some of the identified pathways were also

161 overlapping consisting of miRNAs predicted to influence general signaling pathways and

162 transcriptional programs involved in T cell, NK cell and B cell homeostasis, development,

163 differentiation, trafficking and functional activity: MAPK signaling, p53 signaling, adhesion and

164 adherens junctions, cellular senescence, as well as in macromolecule biosynthesis, metabolism,

165 cell-to-cell interactions, endocytosis, cytoskeleton regulation, and anti-viral pathways

166 (Supplementary Fig. 2). Importantly, the analysis identified miRNA target pathways predicted to

167 influence B and T cell receptor signaling and effector functions: MAPK, mTOR, PI3K-Akt, Ras
168 signaling (Supplementary Fig. 2).

169 We also examined the 20 miRNAs with the highest median baseline expression level in each cell
170 type and found that the highly expressed miRNAs are largely overlapping (Supplementary Table
171 1). There were 22 miRNAs that were in the top 20 for at least two cell subsets (Supplementary
172 Table 1).

173

174 *miRNA changes over time after vaccination*

175 Overall, miRNA profiles in B cells, CD8+ T cells, and CD4+ T cells were stable and barely
176 changed after influenza vaccination. We did not discover significant expression changes ($q < 0.1$)
177 in CD4+ T cells or B cells. In CD8+ T cells, the expression of only six miRNAs (miR-143-3p,
178 miR-152, miR-196a-5p, miR-548f, miR-9-3p, and miR-9-5p) decreased on Day 28 following
179 influenza vaccination. Interestingly, NK cell miRNA expression was much more dynamic and
180 changes were identified earlier, with 142 miRNAs exhibiting significant expression changes on
181 Day 3 following vaccination (Supplementary Table 2). Pathway analysis of the predicted targets
182 of the top NK cell miRNAs ($n=24$), indicated the regulation of the following pathways: ErbB
183 signaling pathway ($p=2.38E^{-06}$), Hippo signaling pathway ($p=1.98E^{-05}$), Wnt signaling pathway
184 ($p=3.04E^{-05}$), MAPK signaling pathway ($p=7.40E^{-05}$), Ras signaling pathway ($p=0.001$) and
185 mTOR signaling pathway ($p=0.001$) among others (data not shown).

186

187 *miRNAs correlated with influenza vaccine response*

188 Since the expression of miRNAs in B and T lymphocytes was stable across timepoints, we first
189 explored if the baseline expression level of multiple miRNAs in each cell type correlated with

190 influenza vaccine-induced (Day 28 – Day 0) HAI response (Fig. 1B, Supplementary Table 3).
191 We identified 39 miRNAs with baseline expression significantly correlated with HAI response
192 (Fig. 1B, $p < 0.01$). Importantly, for nine of the miRNAs (23% of the identified miRNAs), the
193 response correlations were significant across more than one cell subset (Fig. 1B at $p < 0.01$). For
194 example, the positive correlation between miR-331-3p expression and HAI was significant for B
195 cells, CD4+ T cells, and NK cells ($p < 0.01$, Supplementary Table 3, Fig. 1B), while the miR-331-
196 3p correlation in CD8+ T cells was suggestive ($p = 0.016$, Supplementary Table 3). Our results
197 also indicate a large overlap in the HAI-correlated miRNAs between CD8+ T cells and NK cells
198 (6/14 NK miRNAs also found in CD8+ T cells) (Fig. 1B, Supplementary Table 3). Importantly,
199 the baseline expression levels of three miRNAs – miR-150-3p, miR-4443, and miR-629-5p –
200 were significantly correlated with all three immune outcomes (HAI, VNA, B cell ELISPOT) in
201 one or more cell subsets (Fig. 1C and D), which indicates the importance of these miRNAs in the
202 regulation of influenza-specific humoral immunity. miRNAs correlated with VNA and memory
203 B cell ELISPOT responses are listed in Supplementary Table 3, respectively. Of note, the same
204 14 miRNAs correlated with B cell ELISPOT response in CD4+ T cells were also correlated with
205 B cell ELISPOT response in the CD8+ T cell samples.

206

207 *Modeling of influenza vaccine-induced immune outcomes*

208 It is expected that multiple miRNAs work in concert to regulate immune response. Thus, a
209 multivariable model, which jointly models the miRNAs in relation to the immune outcomes,
210 could be a more powerful approach to identify predictive miRNAs compared to the “per
211 miRNA” correlation analysis. Therefore, we next applied elastic net regularized linear regression
212 modeling of immune outcomes as a function of miRNA expression. This joint modeling revealed

213 several sets of miRNAs expressed in the different cell subsets that were collectively associated
214 with and predictive of influenza vaccine-induced response outcomes. Figure 2 illustrates the
215 correlation coefficients for the individual miRNAs baseline expression associated with each
216 model. The top two models from our analysis efforts refer to baseline miRNA expression in
217 CD4⁺ T cells correlated with both HAI (Fig. 2A) and VNA (Fig. 2B) responses, with extensive
218 overlap in the identified miRNAs. Similarly, baseline miRNA expression in CD8⁺ and B cells
219 correlated with VNA response and both models contained miR-4792 and miR-331-3p (Fig. 2C
220 and D). For the two top models (Fig. 2A and B), we performed pathway enrichment analysis (as
221 outlined in Statistical Analysis) on the putative target genes. These results are summarized in
222 Fig. 3 and represent evidence for CD4⁺ T cell miRNA influence on the following biological
223 processes and signaling pathways impacting immune response: carbohydrate and lipid
224 metabolism, endocytosis and cytoskeleton regulation, cell adhesion and adherens junctions,
225 TGF- β signaling, MAPK signaling, p53 signaling, PI3K-Akt signaling and C-type lectin receptor
226 signaling pathways among others. Our predictive modeling efforts of immune outcomes as a
227 function of miRNAs post-vaccination revealed only a small number of CD4⁺ T cell/NK cell
228 miRNAs correlated with influenza-specific memory B cell ELISPOT response or HAI titer
229 (Supplementary Fig. 3A, B and C).

230

231 **Discussion**

232 Our study assessed miRNA expression before/after influenza vaccination in four major
233 lymphocyte cell types (CD4⁺ T cell, CD8⁺ T cell, B cell, and NK cell) and demonstrated stable
234 miRNA expression profiles over time (with the exception of NK cell miRNAs) and noticeably
235 overlapping miRNAs expressed across different cell types. The interrogation of lymphocyte

236 subset-specific miRNAs at baseline revealed miRNA control of both common and unique
237 functional pathways. Among the targeted unique pathways are pathways closely involved in
238 functional activity of specific cell types. These include the TGF-beta signaling pathway,
239 apoptosis and the related to cell cycle control/longevity FoxO signaling pathway in CD4+ T
240 cells; the PI3K-Akt signaling pathway important for the B cell development/differentiation in B
241 cells; and the Ras signaling cascade, triggered downstream of B cell receptor to regulate B cell
242 survival and function. miRNAs also regulated relatively common pathways linked to metabolism
243 and proliferation, cellular senescence, cell adhesion-related pathways, MAPK signaling, p53
244 signaling, as well as endocytosis, cytoskeleton regulation, and anti-viral pathways. It is likely
245 that the common pathways reflect the cellular housekeeping activity, cell cycle progression,
246 cytoskeletal functions and metabolism necessary to support lymphocyte activation,
247 differentiation, proliferation, and functional/immune activity.

248 Although we expected to find more pronounced changes in cellular miRNA expression levels -
249 across timepoints relative to vaccination (baseline, Day 3, Day 28), we found that miRNAs in B
250 cells, CD4+ T cells, and CD8+T cells were relatively stable over time following vaccination.
251 Possible explanations of this observation include: sub-optimal timing of miRNA expression
252 assessment following vaccination (i.e., miRNA expression changes were detectable at other
253 timepoints); miRNA expression changes existed in antigen-specific cells and were missed with
254 global miRNA expression assessment; or influenza vaccination did not alter significantly the
255 host miRNA expression landscape. Interestingly, NK cells exhibited significant changes in
256 miRNA expression at Day 3 post-vaccination relative to baseline. Several of these NK miRNAs
257 have been implicated in biological activities that impact NK cell activity. Expression levels of
258 miR152 changed significantly on Day 3 in NK cells, as well as on Day 28 in CD8+ T cells.

259 miR152 has been demonstrated to control HLA-G expression and NK cell-mediated cytolytic
260 activity [19].

261 Another interesting finding, miR-125b-5p, has been reported to inhibit IRF4, which leads to
262 increased expression of MICA a ligand for the NK cell activating receptor NKG2D [20].
263 Downregulation of this molecule after vaccination would promote enhanced NK cell activity.

264 NK cells are important innate lymphocytes that have innate immune memory and are able to
265 significantly regulate adaptive immune responses after vaccination [21]. For example, NK cell
266 cytolytic activity was demonstrated to affect antigen persistence and/or target responding T cells
267 after vaccination [21, 22]. Other NK cell functional activities (secretion of IFN γ and expression
268 and activating/inhibitory receptors) have been linked to the stimulation of antigen-presenting
269 cells following vaccination [23]. This suggests that changes in NK cell miRNA expression
270 following vaccination can have direct or indirect effect on adaptive immune responses after
271 influenza vaccination. Other miRNAs exhibiting NK cell expression changes include miR126-
272 5p, which has been implicated in the macrophage response to LPS [24] and in endothelial cell
273 angiogenesis, [25] and miR148a-3p, which in concert with other miRNAs has been demonstrated
274 to modulate plasma cell differentiation in B cells [26]. miR-339-5p has been shown to regulate
275 lymphocyte tissue migration [27, 28] and to control inflammation by inhibiting IKK- β and IKK-
276 ϵ activity [29]. Further investigation will be necessary in order to understand what role, if any,
277 these NK cell miRNAs play in cell activation, proliferation, or immune function.

278 Of great interest to vaccinology is the discovery of miRNAs that may regulate immune
279 response and/or potentially serve as biomarkers of vaccine-induced immunity for inclusion in an
280 immune signature predictive of optimal (or suboptimal) vaccine response. In this study, three
281 baseline miRNAs (miR-150-3p, miR-629-5p and miR-4443) were significantly negatively

282 correlated with all three immune outcomes (HAI titer, VNA titer and memory B cell ELISPOT
283 response) when data from all four cell types were analyzed (Fig. 1C and D). miR-150-3p has
284 previously been reported to regulate key biological processes such as inflammation, apoptotic
285 pathways and cell proliferation [30]. miR-150 overexpression has been found to profoundly
286 impair formation of mature B cells and their functional activity with smaller effect on the
287 development of T cells, granulocytes and macrophages [31]. Similarly, in our study, increased
288 miR-150 expression in B cells was negatively correlated ($p=0.00038$) with memory B cell
289 ELISPOT response after influenza vaccine, likely due to mature B cell suppression/suppression
290 of germinal center memory B cell differentiation [32], while the increased expression in T cells
291 ($CD4^+$ and $CD8^+$ T cells) was negatively correlated with the HAI/VNA titer. It was previously
292 established that the intracellular miR-150 expression in T cells (e.g., $CD4^+$ T helper cells) is
293 downregulated upon T cell activation to control key genes underlying T cell functions due to its
294 quick extracellular release in exosomes [33, 34]. Importantly, extracellular miR-150 level
295 (corresponding to the level of downregulation of intracellular miR-150 in T cells) has been
296 established as a reliable serum marker of lymphocyte activation (T cell activation) [35].
297 Moreover, the serum level of miR-150 was found to be elevated in subjects following MF-59-
298 adjuvanted 2009 influenza A (H1N1) vaccination with higher levels observed in subjects with
299 higher antibody titers [33]. This is corroborated by our finding of negative correlation between
300 the intracellular expression of miR-150 in T cells and influenza vaccine-induced HAI/VNA
301 antibody responses. Thus, miR-150 expression emerges as a reliable biomarker of influenza
302 vaccine-induced immunity as identified in a previous study [33] and ascertained by our findings.
303 miR-629 has been investigated as a prognostic marker in cancer and has been implicated
304 primarily in the regulation of proliferation, apoptosis, cell migration and alteration of TGF-

305 beta/Smad signaling (via its target gene TRIM33) [36, 37]. Its expression has not been
306 previously linked to immune response to vaccination/infection as suggested by our findings.
307 miR-4443 has been connected to the regulation of key cellular signaling pathways such as the
308 NF- κ B, TGF- β and the Ras signaling pathways [38]. Increased expression of miR-4443 has been
309 linked to dysfunction in T cells mediated via TNF receptor associated factor 4/TRAF4, and thus
310 it is possible that this miRNA negatively impacts humoral immunity by impairing CD4⁺ T cell
311 function [39]. On the other hand, the Ras GTPases serve as signaling checkpoints in antigen
312 receptors, and Ras signaling (regulated in part by the expression of miR-4443) may play a key
313 role in immune cell activation and function by engaging multiple downstream effectors [40, 41].
314 The Ras signaling pathway downstream of BCR is known to be a critical part of B cell
315 proliferation, differentiation, antigenic activation and functional activity [42]. The Ras-ERK1/2
316 MAPK cascade is also tightly involved in Th2 cell differentiation [43], so it is possible that
317 miRNA expression (miR-4443 and other miRNAs) regulating these signaling pathways may
318 fine-tune critical antigen-driven cellular activities in B and T lymphocytes.

319 Other miRNAs of interest demonstrated significant associations with HAI antibody titer (and
320 not other immune outcomes) after influenza vaccination, but across several cell subsets. For
321 example, the baseline expression of miR-331-3p was positively associated with HAI in B cells,
322 CD4⁺ T cells, and NK cells (Fig. 2).

323 Our predictive modeling efforts of baseline miRNA expression confirmed that indeed miR-
324 331-3p is an important biomarker of influenza vaccine-induced immunity as it was identified as a
325 positive predictor of HAI/VNA antibody titer in CD4⁺ T cells, B cells and CD8⁺ T cells (Fig. 2).
326 miR-331-3p has been demonstrated to inhibit proliferation and support apoptosis via regulating
327 the PI3K/Akt and ERK1/2 pathways [44, 45]. It is possible that miR-331-3p expression regulates

328 cell proliferation in several immune cell types and thus contributes to their functional activities
329 following vaccination. For example, both signaling pathways (altered by the expression of miR-
330 331-3p) are key in regulating B cell metabolic activity, proliferation and differentiation upon
331 antigenic stimulation and thus are likely to influence vaccine-induced immunity [46]. miRNAs
332 of the miR-17–92 locus (i.e., miR-17 and miR-18a) in B and T cells (Fig.2) were also identified
333 as being associated with post-vaccine HAI titer. These miRNAs play an important role in B cell
334 development, differentiation, survival and regulation of class switching, and thus are intimately
335 involved in B cell functionality [47]. The baseline cell expression of miR-15 and miR-223 was
336 found to be associated with post-vaccine HAI titer and/or influenza virus-specific memory B cell
337 ELISPOT response in our study. miR-15 was previously demonstrated to target Bcl2 and to
338 regulate B cell survival, while miR-223 is enriched in the memory B cell compartment and
339 regulates an important transcription factor (LMO2) critical for B cell differentiation, and has
340 been also established as a regulator of activation-induced cytidine deaminase (AID) [48]. AID
341 is an essential enzyme mainly expressed in germinal center B cells that plays a role in somatic
342 hypermutation/antibody diversity and Ig class switching [49]. Thus, both miR-15 and miR-223
343 emerge as plausible regulators of B cell function and biomarkers of influenza. vaccine-induced
344 humoral immunity. The expression of miR-34a-5p in CD4+ T cells was identified as a plausible
345 predictor of influenza vaccine-induced antibody response (Fig. 2). The involvement of miR-34a-
346 5p in plasma cell differentiation (along with miR-125b-5p and miR-101-3p) has been previously
347 demonstrated [26], but its role in regulating T cell functionality is still unclear. Interestingly, the
348 expression of miR-125b-5p has also been identified as a predictor of VNA antibody response in
349 both B cells and CD4+ T cells in our study.

350 The top predictive models from our study (Fig. 2A and B) identified specific baseline miRNAs
351 in CD4⁺ T cells as predictors (or factors associated with) of influenza vaccine-induced
352 HAI/VNA antibody responses, with some overlap in the identified miRNAs (for the HAI and the
353 VNA model). Interestingly, models involving miRNA expression post-vaccination resulted in
354 less robust findings (Supplementary Fig. 3). The pathway enrichment analysis on the putative
355 target genes regulated by the identified baseline miRNAs revealed the impact of several
356 important signaling pathways in CD4⁺ T cells in shaping the influenza vaccine-induced
357 immunity. These include TGF- β signaling, PI3K-Akt signaling, MAPK signaling, p53 signaling,
358 TNF signaling and C-type lectin receptor signaling pathways. Basic cellular activities and
359 functions (regulated by these miRNAs) were also identified as important and impacting influenza
360 vaccine-induced humoral immunity: cell adhesion and adherens junctions, antiviral host
361 response, carbohydrate and lipid metabolism, endocytosis and cytoskeleton regulation.

362 The strengths of our study include the miRNA expression assessment in 4 purified cell subsets
363 (B cells, CD4⁺ T cells, CD8⁺ T cells and NK cells) of subjects before/after influenza vaccination
364 and the robust statistical modeling of influenza vaccine-induced immunity. The limitation is the
365 lack of replication of the identified miRNA biomarkers/pathways in an independent cohort.
366 Important next steps will be experimental validation of the identified miRNAs: co-expression
367 studies of miRNAs and putative targets to provide experimental proof of specific miRNA-
368 mRNA interactions; and experiments revealing how miRNAs modulate target protein expression
369 and how this impacts immune response [50].

370 In conclusion, our study uncovered novel information regarding the complex genetic control of
371 immune pathways, leading to better understanding of immune function regulation. The study

372 also identified plausible predictive biomarkers of influenza vaccine-induced immune response
373 outcomes, that warrant validation in future studies.

374

375 **Data availability**

376 All data is available at ImmPort.org (SDY67).

377

378 **Acknowledgements**

379 We would like to thank the subjects who volunteered to participate in our study. The study was
380 funded by the National Institute of Allergic and Infectious Diseases of the National Institutes of
381 Health (U01 AI 089859/Bioinformatics Approach to Influenza A/H1N1 Vaccine Immune
382 Profiling and R01AI132348), the Human Immunology Project Consortium Infrastructure and
383 Opportunities Fund, and a grant from the Mayo Clinic Biomarker Discovery program (grant
384 C4330915).

385 The content is solely the responsibility of the authors and does not necessarily represent the
386 official views of the National Institutes of Health.

387

388 **Conflict of Interest**

389 Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials
390 being conducted by Merck Research Laboratories. Dr. Poland provides consultative advice to
391 AiZtech; AstraZeneca; Emergent; GlaxoSmithKline; Invivyd; Johnson & Johnson/Janssen;
392 Medicago; Medscape/WebMD; Merck & Co. Inc.; Moderna; NovaSource/NorthStar Energy;
393 Novavax; Ocugen; Regeneron; Sanofi; Syneos Health; and Valneva. Dr. Poland is an adviser to
394 the White House and World Health Organization on COVID-19 vaccines and monkeypox,

395 respectively. Drs. Poland and Ovsyannikova hold patents related to vaccinia and measles peptide
396 vaccines. Drs. Kennedy, Poland, and Ovsyannikova hold a patent related to vaccinia peptide
397 vaccines. Drs. Poland, Kennedy, Ovsyannikova, and Haralambieva hold a patent related to the
398 impact of single nucleotide polymorphisms on measles vaccine immunity. Drs. Poland,
399 Kennedy, and Ovsyannikova have received grant funding from ICW Ventures for preclinical
400 studies on a peptide-based COVID-19 vaccine. Dr. Kennedy has received funding from Merck
401 Research Laboratories to study waning immunity to mumps vaccine. Dr. Kennedy also offers
402 consultative advice on vaccine development to Merck & Co. and Sanofi Pasteur. These activities
403 have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in
404 compliance with Mayo Clinic Conflict of Interest policies.

405

406

407

408

409

410

411

412

413

414

415

416

417


418 **Figure Legends**

419

420 **Fig. 1** Baseline miRNA expression and its influence on humoral immune response outcomes
421 following influenza vaccination

422 **A.** Venn diagram of miRNAs expressed within each cell type. **B.** Correlation between baseline
423 miRNA expression and HAI antibody titer following influenza vaccination. Correlation plot
424 illustrating the associations between baseline miRNA and HAI antibody titer (Day 28 -Day0) for
425 each cell subset (CD4+ T cell, CD8+ T cell, B cell, and NK cell) **C.** Baseline miRNAs
426 significantly correlated with all humoral immune outcomes (change in HAI antibody titer, VNA
427 antibody titer and B cell ELISPOT response) for each cell subset. The color of the correlation
428 represents the direction (red, negatively associated, blue positively associated with the immune
429 outcome). The size of the circle represents the strength of the correlation. The color intensity
430 scale to the right of the figure is a scale for the Spearman's correlations with darker colors
431 indicating stronger correlation. Blank cells indicate that the correlation with the specific miRNA
432 was zero in the associated cell type, and cells with a "?" indicate that the miRNA was not present
433 (not measured) in the cell type. * $p < 0.01$, ** $p < 0.001$. **D.** miRNAs significantly correlated with HAI,
434 VNA, and B cell ELISPOT. Correlations are with the immune response deltas (Day28 – Day0).
435 $P < 0.01$ was used as the cut-off.

436



437

438

439

440


441

442

443 **Fig.2 Predictive modeling of baseline miRNA expression on influenza vaccine-induced**
 444 **humoral immune outcomes**

445 Modeling was performed as described in Statistical Analysis. The baseline CD4+ T cell miRNAs
 446 predictive of influenza vaccine-induced HAI titer are depicted in **A**. and those predictive of VNA
 447 titer are depicted in **B**. The baseline B cell miRNAs and CD8+ T cell miRNAs predictive of
 448 influenza vaccine-induced VNA titer are depicted in **C** and **D**, respectively. The standardized
 449 linear regression coefficients are the estimated change in the response for a one standard
 450 deviation change in the associated miRNA expression. Positive coefficient values (bars
 451 extending to the right of the centerpoint of the x-axis) indicate that an increase in the miRNA
 452 expression is associated with an increase in the immune response outcome, while negative
 453 coefficient values (bars extending to the left of the centerpoint of the x-axis) indicate that as the
 454 miRNA expression increases the immune response outcome decreases.

455



456

457

458 **Fig. 3 Pathway analysis of target genes regulated by baseline CD4+ T cell-specific miRNAs**


459 **influencing influenza vaccine-induced HAI/VNA antibody titer**

460 Enrichment pathway analysis performed (see. Statistical Analysis) on the predicted gene targets

461 of baseline CD4+ T cell miRNAs associated with **A.** HAI titer or **B.** with VNA titer. The bar

462 length corresponds to the significance level of enrichment. Only pathways with $q < 0.0001$ are

463 included in the graph.



464

465

466

467 **Table 1. Cell type-specific miRNAs**

468

Table 1. Cell Type-Specific miRNAs			
B cells (n=16)	NK cells (n=22)	CD4 T cells (n=34)	CD8 T cells (n=3)
hsa-miR-1295a	hsa-miR-10a-3p	hsa-let-7e-3p	hsa-miR-199a-5p
hsa-miR-129-5p	hsa-miR-1908	hsa-let-7g-3p	hsa-miR-584-5p
hsa-miR-1303	hsa-miR-196b-5p	hsa-miR-1254	hsa-miR-9-3p
hsa-miR-138-5p	hsa-miR-20b-3p	hsa-miR-125b-2-3p	
hsa-miR-195-3p	hsa-miR-2355-3p	hsa-miR-1261	
hsa-miR-195-5p	hsa-miR-338-3p	hsa-miR-1285-5p	
hsa-miR-3150b-3p	hsa-miR-429	hsa-miR-1299	
hsa-miR-3614-5p	hsa-miR-432-5p	hsa-miR-1976	
hsa-miR-4491	hsa-miR-4489	hsa-miR-296-5p	
hsa-miR-5196-3p	hsa-miR-4665-5p	hsa-miR-34a-5p	
hsa-miR-574-3p	hsa-miR-4755-5p	hsa-miR-365a-3p	
hsa-miR-577	hsa-miR-4772-3p	hsa-miR-365b-3p	
hsa-miR-582-3p	hsa-miR-4772-5p	hsa-miR-3687	
hsa-miR-629-3p	hsa-miR-550a-3-5p	hsa-miR-374b-3p	
hsa-miR-708-3p	hsa-miR-550a-5p	hsa-miR-4536-5p	
hsa-miR-708-5p	hsa-miR-6131	hsa-miR-455-5p	
	hsa-miR-628-5p	hsa-miR-4688	
	hsa-miR-641	hsa-miR-4781-3p	
	hsa-miR-873-3p	hsa-miR-4791	
	hsa-miR-876-3p	hsa-miR-506-3p	
	hsa-miR-92a-2-5p	hsa-miR-508-3p	
	hsa-miR-93-3p	hsa-miR-508-5p	
		hsa-miR-5090	
		hsa-miR-509-3-5p	
		hsa-miR-509-3p	
		hsa-miR-513c-5p	
		hsa-miR-514a-3p	
		hsa-miR-548b-5p	
		hsa-miR-548q	
		hsa-miR-6511a-3p	
		hsa-miR-6511b-3p	
		hsa-miR-659-5p	
		hsa-miR-676-3p	
		hsa-miR-939-5p	

469 miRNAs with a median count of less than or equal to 4 were not included.

470

471

472

473

474 **References**

475

476 [1] Connerty P, Ahadi A, Hutvagner G. RNA Binding Proteins in the miRNA Pathway. *Int J*
477 *Mol Sci.* 2015;17.

478 [2] Atherton LJ, Jorquera PA, Bakre AA, Tripp RA. Determining Immune and miRNA
479 Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types. *Front Immunol.*
480 2019;10:2323.

481 [3] Oshiumi H. Circulating Extracellular Vesicles Carry Immune Regulatory miRNAs and
482 Regulate Vaccine Efficacy and Local Inflammatory Response After Vaccination. *Front*
483 *Immunol.* 2021;12:685344.

484 [4] Abu-Izneid T, AlHajri N, Ibrahim AM, Javed MN, Salem KM, Pottou FH, et al. Micro-
485 RNAs in the regulation of immune response against SARS CoV-2 and other viral infections. *J*
486 *Adv Res.* 2021;30:133-45.

487 [5] Haralambieva IH, Kennedy RB, Simon WL, Goergen KM, Grill DE, Ovsyannikova IG, et al.
488 Differential miRNA expression in B cells is associated with inter-individual differences in
489 humoral immune response to measles vaccination. *PLoS One.* 2018;13:e0191812.

490 [6] Haralambieva IH, Painter SD, Kennedy RB, Ovsyannikova IG, Lambert ND, Goergen KM,
491 et al. The impact of immunosenescence on humoral immune response variation after influenza
492 A/H1N1 vaccination in older subjects. *PLoS One.* 2015;10:e0122282.

493 [7] Haralambieva IH, Ovsyannikova IG, Kennedy RB, Zimmermann MT, Grill DE, Oberg AL,
494 et al. Transcriptional signatures of influenza A/H1N1-specific IgG memory-like B cell response
495 in older individuals. *Vaccine.* 2016;34:3993-4002.

496 [8] Kennedy RB, Ovsyannikova IG, Haralambieva IH, Oberg AL, Zimmermann MT, Grill DE,
497 et al. Immunosenescence-Related Transcriptomic and Immunologic Changes in Older
498 Individuals Following Influenza Vaccination. *Front Immunol.* 2016;7:450.

499 [9] Haralambieva IH, Zimmermann MT, Ovsyannikova IG, Grill DE, Oberg AL, Kennedy RB,
500 et al. Whole Transcriptome Profiling Identifies CD93 and Other Plasma Cell Survival Factor
501 Genes Associated with Measles-Specific Antibody Response after Vaccination. *PLoS One.*
502 2016;11:e0160970.

503 [10] Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Zimmermann MT, Grill
504 DE, et al. Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing
505 antibody response to measles vaccine. *Hum Genet.* 2017;136:421-35.

506 [11] Sun Z, Evans J, Bhagwate A, Middha S, Bockol M, Yan H, et al. CAP-miRSeq: a
507 comprehensive analysis pipeline for microRNA sequencing data. *BMC Genomics.* 2014;15:423.

508 [12] Friedlander MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2 accurately
509 identifies known and hundreds of novel microRNA genes in seven animal clades. *Nucleic Acids*
510 *Res.* 2012;40:37-52.

511 [13] Robinson MD, Oshlack A. A scaling normalization method for differential expression
512 analysis of RNA-seq data. *Genome Biol.* 2010;11:R25.

513 [14] Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential
514 expression analysis of digital gene expression data. *Bioinformatics.* 2010;26:139-40.

- 515 [15] Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes.
516 *Biometrics*. 1986;42:121-30.
- 517 [16] Hastie TT, Tibshirani R, Friedman J. *The Elements of Statistical Learning: Data Mining,*
518 *Inference, and Prediction*. Second Edition ed: Springer; 2009.
- 519 [17] Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The multiMiR R
520 package and database: integration of microRNA-target interactions along with their disease and
521 drug associations. *Nucleic Acids Res*. 2014;42:e133.
- 522 [18] Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment
523 tool for interpreting omics data. *Innovation (Camb)*. 2021;2:100141.
- 524 [19] Manaster I, Goldman-Wohl D, Greenfield C, Nachmani D, Tsukerman P, Hamani Y, et al.
525 MiRNA-mediated control of HLA-G expression and function. *PLoS One*. 2012;7:e33395.
- 526 [20] Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, et al. Inhibition of
527 bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and
528 sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-
529 miR-125b interplay. *J Hematol Oncol*. 2016;9:134.
- 530 [21] Cox A, Cevik H, Feldman HA, Canaday LM, Lakes N, Waggoner SN. Targeting natural
531 killer cells to enhance vaccine responses. *Trends Pharmacol Sci*. 2021;42:789-801.
- 532 [22] Rydzynski CE, Waggoner SN. Boosting vaccine efficacy the natural (killer) way. *Trends*
533 *Immunol*. 2015;36:536-46.
- 534 [23] Goodier MR, Riley EM. Regulation of the human NK cell compartment by pathogens and
535 vaccines. *Clin Transl Immunology*. 2021;10:e1244.
- 536 [24] Huang J, Zhu L, Qiu C, Xu X, Zhang L, Ding X, et al. MicroRNA miR-126-5p Enhances
537 the Inflammatory Responses of Monocytes to Lipopolysaccharide Stimulation by Suppressing
538 Cylindromatosis in Chronic HIV-1 Infection. *J Virol*. 2017;91.
- 539 [25] Zhou Q, Anderson C, Hanus J, Zhao F, Ma J, Yoshimura A, et al. Strand and Cell Type-
540 specific Function of microRNA-126 in Angiogenesis. *Mol Ther*. 2016;24:1823-35.
- 541 [26] Tsai DY, Hung KH, Lin IY, Su ST, Wu SY, Chung CH, et al. Uncovering MicroRNA
542 Regulatory Hubs that Modulate Plasma Cell Differentiation. *Sci Rep*. 2015;5:17957.
- 543 [27] Shan W, Li J, Bai Y, Lu X. miR-339-5p inhibits migration and invasion in ovarian cancer
544 cell lines by targeting NACC1 and BCL6. *Tumour Biol*. 2016;37:5203-11.
- 545 [28] Zhou C, Lu Y, Li X. miR-339-3p inhibits proliferation and metastasis of colorectal cancer.
546 *Oncol Lett*. 2015;10:2842-8.
- 547 [29] Zhang Y, Wei G, Di Z, Zhao Q. miR-339-5p inhibits alcohol-induced brain inflammation
548 through regulating NF-kappaB pathway. *Biochem Biophys Res Commun*. 2014;452:450-6.
- 549 [30] Girardi C, De Pitta C, Casara S, Calura E, Romualdi C, Celotti L, et al. Integration analysis
550 of microRNA and mRNA expression profiles in human peripheral blood lymphocytes cultured in
551 modeled microgravity. *Biomed Res Int*. 2014;2014:296747.
- 552 [31] Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in
553 mature B and T cells, blocks early B cell development when expressed prematurely. *Proc Natl*
554 *Acad Sci U S A*. 2007;104:7080-5.
- 555 [32] Inoue T. Memory B cell differentiation from germinal centers. *Int Immunol*. 2023;35:565-
556 70.
- 557 [33] de Candia P, Torri A, Gorletta T, Fedeli M, Bulgheroni E, Cheroni C, et al. Intracellular
558 modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation.
559 *PLoS One*. 2013;8:e75348.

- 560 [34] Pagani M, Rossetti G, Panzeri I, de Candia P, Bonnal RJ, Rossi RL, et al. Role of
561 microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation. *Immunol Rev.*
562 2013;253:82-96.
- 563 [35] de Candia P, Torri A, Pagani M, Abrignani S. Serum microRNAs as Biomarkers of Human
564 Lymphocyte Activation in Health and Disease. *Front Immunol.* 2014;5:43.
- 565 [36] Yan H, Li Q, Wu J, Hu W, Jiang J, Shi L, et al. MiR-629 promotes human pancreatic
566 cancer progression by targeting FOXO3. *Cell Death Dis.* 2017;8:e3154.
- 567 [37] Ledoux D, Mereau A, Dauchel MC, Barritault D, Courty J. Distribution of basic fibroblast
568 growth factor binding sites in various tissue membrane preparations from adult guinea pig.
569 *Biochem Biophys Res Commun.* 1989;159:290-6.
- 570 [38] Mao Y, Shen J, Wu Y, Wenjing R, Zhu F, Duan S. Aberrant expression of microRNA-4443
571 (miR-4443) in human diseases. *Bioengineered.* 2022;13:14770-9.
- 572 [39] Qi Y, Zhou Y, Chen X, Ye L, Zhang Q, Huang F, et al. MicroRNA-4443 Causes CD4+ T
573 Cells Dysfunction by Targeting TNFR-Associated Factor 4 in Graves' Disease. *Front Immunol.*
574 2017;8:1440.
- 575 [40] Sadeghi Shaker M, Rokni M, Mahmoudi M, Farhadi E. Ras family signaling pathway in
576 immunopathogenesis of inflammatory rheumatic diseases. *Front Immunol.* 2023;14:1151246.
- 577 [41] Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. *J Cell Sci.*
578 2005;118:843-6.
- 579 [42] McLaurin JD, Weiner OD. Multiple sources of signal amplification within the B-cell
580 Ras/MAPK pathway. *Mol Biol Cell.* 2019;30:1610-20.
- 581 [43] Yamashita M, Shinnakasu R, Asou H, Kimura M, Hasegawa A, Hashimoto K, et al. Ras-
582 ERK MAPK cascade regulates GATA3 stability and Th2 differentiation through ubiquitin-
583 proteasome pathway. *J Biol Chem.* 2005;280:29409-19.
- 584 [44] Zhao D, Sui Y, Zheng X. MiR-331-3p inhibits proliferation and promotes apoptosis by
585 targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer. *Oncol Rep.*
586 2016;35:1075-82.
- 587 [45] Epis MR, Giles KM, Candy PA, Webster RJ, Leedman PJ. miR-331-3p regulates
588 expression of neuropilin-2 in glioblastoma. *J Neurooncol.* 2014;116:67-75.
- 589 [46] Jellusova J, Rickert RC. The PI3K pathway in B cell metabolism. *Crit Rev Biochem Mol*
590 *Biol.* 2016;51:359-78.
- 591 [47] Lou Z, Casali P, Xu Z. Regulation of B Cell Differentiation by Intracellular Membrane-
592 Associated Proteins and microRNAs: Role in the Antibody Response. *Front Immunol.*
593 2015;6:537.
- 594 [48] Zan H, Casali P. Epigenetics of Peripheral B-Cell Differentiation and the Antibody
595 Response. *Front Immunol.* 2015;6:631.
- 596 [49] Park SR. Activation-induced Cytidine Deaminase in B Cell Immunity and Cancers.
597 *Immune Netw.* 2012;12:230-9.
- 598 [50] Riolo G, Cantara S, Marzocchi C, Ricci C. miRNA Targets: From Prediction Tools to
599 Experimental Validation. *Methods Protoc.* 2020;4.